Clovis Oncology, Inc. Form SC 13D/A March 10, 2015

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13D (Rule 13d-101)

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)1

Clovis Oncology, Inc. (Name of Issuer)

Common Stock, \$.001 par value

(Title of Class of Securities)

189464100 (CUSIP Number)

Domain Associates, LLC Ropes & Gray LLP

One Palmer Square 1211 Avenue of the Americas

Princeton, NJ 08542 New York, NY 10036

Attn: Kathleen K. Schoemaker Attn: Morri H. Weinberg, Esq.

Tel: (609) 683-5656 Tel: (212) 596-9000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 3, 2015

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. []

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

¹ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter

Edgar Filing: Clovis Oncology, Inc. - Form SC 13D/A

disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (VOLUNTARY)						
					Domain Partners VII,		
	EIN No.:			L.P.			
2.	СНЕСК ТН	IE APPROPRIAT	E BOX IF A MEMBER OF A GROUP*	(a) (b)	[X]		
3.	SEC USE O	NLY					
4.	SOURCE OF FUNDS			Not Applicable			
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)						
6.	CITIZENSHIP OR PLACE OF ORGANIZATION				Delaware		
NUMBE		7.	SOLE VOTING POWER		2,081,745		
SHARES BENEFICOWNED	CIALLY	8.	SHARED VOTING POWER		0		
EACH REPORT PERSON		9.	SOLE DISPOSITIVE POWER		2,081,745		
WITH		10.	SHARED DISPOSITIVE POWER		0		
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				2,081,745		
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES						
13.	PERCENT (OF CLASS REPR	ESENTED BY AMOUNT IN ROW (11))	6.1%		

14. TYPE OF REPORTING PERSON

PN

Edgar Filing: Clovis Oncology, Inc. - Form SC 13D/A

CUSIP NO. 189464100

1.	NAME OF R S.S. OR I.R.S (VOLUNTAI						
	EIN No.:			DP VII Associates, L.P.			
	ZII (I (O.,			2.1.			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*			(a) (b)	[X]		
3.	SEC USE ON	ILY					
4.	SOURCE OF FUNDS CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)						
					Not Applicable		
5.					[]		
6.	CITIZENSHIP OR PLACE OF ORGANIZATION				Delaware		
NUMBE	ED OE	7.	SOLE VOTING POWER		35,506		
SHARES					0		
BENEFI OWNED	ICIALLY ORY	8.	SHARED VOTING POWER				
EACH REPORT PERSON	ΓING	9.	SOLE DISPOSITIVE POWER		35,506		
WITH	`	10.	SHARED DISPOSITIVE POWER		0		
11.	AGGREGAT REPORTING	35,506					
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES						
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)				Less than 0.1%		

TYPE OF REPORTING PERSON

PN

3

14.

1.	NAME OF I S.S. OR I.R. (VOLUNTA						
	EIN No.:				Domain Associates, LLC		
2.	СНЕСК ТН	E APPROPRIAT	E BOX IF A MEMBER OF A GROUP*	(a) (b)	[X] []		
3.	SEC USE O	NLY					
4.	SOURCE OF FUNDS				Not Applicable		
5.	CHECK BO	[]					
6.	CITIZENSHIP OR PLACE OF ORGANIZATION				Delaware		
NUMBEI		7.	SOLE VOTING POWER			32,760	
SHARES BENEFIC OWNED	CIALLY	8.	SHARED VOTING POWER			C	
EACH REPORT PERSON	ING	9.	SOLE DISPOSITIVE POWER			32,760	
WITH		10.	SHARED DISPOSITIVE POWER	t		C	
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
12.		X IF THE AGGR S CERTAIN SHA	EGATE AMOUNT IN ROW (11) RES				
13.	PERCENT (OF CLASS REPR	ESENTED BY AMOUNT IN ROW (11)		Less th	an 0.1%	

OO

14. TYPE OF REPORTING PERSON

AMENDMENT NO. 2 TO SCHEDULE 13D

Reference is hereby made to the statement on Schedule 13D filed with the Securities and Exchange Commission (the "Commission") by the Reporting Persons with respect to the Common Stock of the Issuer on November 21, 2011 and Amendment No. 1 thereto filed on June 5, 2013 (as so amended, the "Schedule 13D"). Terms defined in the Schedule 13D are used herein as so defined.

Item Interest in Securities of the Issuer.

5.

Item 5(a) is hereby amended and restated as follows:

The information requested by this paragraph is incorporated herein by reference to the cover pages to this Amendment No. 2 to Schedule 13D. Ownership percentages are based on 34,017,885 shares of Common Stock outstanding as of February 20, 2015, as reported in the Issuer's Report on Form 10K for the period ended December 31, 2014 filed with the Commission on February 27, 2015.

In addition to the shares that OPSA VII indirectly beneficially owns in its capacity as the general partner of DP VII and DP VIIA, OPSA VII directly beneficially owns 41,813 shares of Common Stock, or approximately 0.1% of the Common Stock outstanding.

In addition, James C. Blair directly beneficially owns (i) 12,413 shares of Common Stock issuable upon exercise of a presently-exercisable option to purchase 12,413 shares of Common Stock, at an exercise price of \$11.02 per share, which was granted on August 24, 2011 and expires on August 24, 2021; (ii) 12,413 shares of Common Stock issuable upon exercise of a presently-exercisable option to purchase Common Stock, at an exercise price of \$19.46 per share, which was granted on June 14, 2012 and expires on June 14, 2022; (iii) 12,414 shares of Common Stock issuable upon exercise of a presently-exercisable option to purchase Common Stock, at an exercise price of \$71.11 per share, which was granted on June 13, 2013 and expires on June 13, 2023; and (iv) 8,276 shares of Common Stock issuable upon exercise of a presently-exercisable option to purchase Common Stock, representing the vested portion of an option to purchase 12,414 shares of Common Stock, at an exercise price of \$44.52 per share, which was granted on June 12, 2014 and expires on June 12, 2024.

Item of the Schedule 13D is hereby amended and restated as follows: 5(c).

On March 3, 2015, DP VII distributed in kind 500,000 shares of Common Stock pro rata to its partners, including 41,813 shares to OPSA VII. On March 5, 2015, DP VII A sold 8,528 shares of Common Stock in open market transactions, at an average price of \$77.6963 per share.

SIGNATURES

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: March 9, 2015

DOMAIN PARTNERS VII, L.P.

By: One Palmer Square Associates VII,

L.L.C., General Partner

By: /s/ Kathleen K. Schoemaker

Managing Member

DP VII ASSOCIATES, L.P.

By: One Palmer Square Associates VII,

L.L.C., General Partner

By: /s/ Kathleen K. Schoemaker

Managing Member

DOMAIN ASSOCIATES, L.L.C.

By: /s/ Kathleen K. Schoemaker

Managing Member